End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4384 USD | +2.62% | +3.89% | -10.00% |
04-30 | Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product | CI |
04-30 | Akili, Inc. to Reduce Workforce | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe1st Jan change | Capi. | |
---|---|---|
-10.00% | 34.46M | |
+11.29% | 225B | |
+8.76% | 186B | |
+12.90% | 135B | |
+25.95% | 107B | |
+0.34% | 63.56B | |
+11.08% | 51.04B | |
+5.62% | 51.32B | |
+6.28% | 43.3B | |
+4.80% | 36.99B |
- Stock Market
- Equities
- AKLI Stock
- News Akili, Inc.
- Transcript : Akili, Inc., Q3 2023 Earnings Call, Nov 09, 2023